Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2015 3
2016 3
2018 2
2019 3
2020 2
2021 6
2022 12
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He K, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S; SAPPHIRE Investigators. Borghaei H, et al. Ann Oncol. 2024 Jan;35(1):66-76. doi: 10.1016/j.annonc.2023.10.004. Epub 2023 Oct 20. Ann Oncol. 2024. PMID: 37866811 Clinical Trial.
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database.
Côté J, LeBlanc R, Mian H, Chu MP, McCurdy A, Masih-Khan E, Su J, Jimenez-Zepeda VH, Song K, Louzada M, White D, Sebag M, Reiman A, Stakiw J, Kotb R, Bergstrom D, Aslam M, Kaedbey R, Venner CP, Gul E, Reece D. Côté J, et al. Among authors: reiman a. Blood Cancer J. 2023 Sep 5;13(1):137. doi: 10.1038/s41408-023-00905-8. Blood Cancer J. 2023. PMID: 37669949 Free PMC article.
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda VH, Su J, Masih-Khan E, Visram A, Louzada M, Song K, White D, Sebag M, Stakiw J, Reiman A, Aslam M, Bergstrom D, Kotb R, Kaedbey R, Gul E, Reece D, Venner CP. McCurdy A, et al. Among authors: reiman a. Blood Cancer J. 2023 Aug 28;13(1):129. doi: 10.1038/s41408-023-00888-6. Blood Cancer J. 2023. PMID: 37635183 Free PMC article. No abstract available.
How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership.
Bridges S, Fowler S, McLaughlin L, Robichaud M, Ridgway B, Reece D, Song K, Dalrymple L, Sully R, Nason S, Rowland S, MacDonald T, Paine W, Gulliver A, Reiman A. Bridges S, et al. Among authors: reiman a. Res Involv Engagem. 2023 Jul 29;9(1):60. doi: 10.1186/s40900-023-00476-9. Res Involv Engagem. 2023. PMID: 37516883 Free PMC article.
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda VH, Su J, Masih-Khan E, Visram A, Louzada M, Song K, White D, Sebag M, Stakiw J, Reiman A, Aslam M, Bergstrom D, Kotb R, Kaedbey R, Gul E, Reece D, Venner CP. McCurdy A, et al. Among authors: reiman a. Blood Cancer J. 2023 Jul 20;13(1):111. doi: 10.1038/s41408-023-00883-x. Blood Cancer J. 2023. PMID: 37474492 Free PMC article.
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
McCurdy A, Louzada M, Venner CP, Visram A, Masih-Khan E, Kardjadj M, Jimenez-Zepeda VH, LeBlanc R, Sebag M, Song K, White D, Mian H, Stakiw J, Reiman A, Aslam M, Kotb R, Gul E, Reece D. McCurdy A, et al. Among authors: reiman a. EJHaem. 2022 Aug 31;3(4):1252-1261. doi: 10.1002/jha2.559. eCollection 2022 Nov. EJHaem. 2022. PMID: 36467802 Free PMC article.
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database.
Mian H, LeBlanc R, Louzada M, Masih-Khan E, McCurdy A, Venner CP, Stakiw J, Kardjadj M, Jimenez-Zepeda VH, Sebag M, White D, Aslam M, Song K, Reiman A, Kotb R, Gul E, Reece D. Mian H, et al. Among authors: reiman a. Cancer Med. 2023 Feb;12(4):4357-4362. doi: 10.1002/cam4.5245. Epub 2022 Sep 26. Cancer Med. 2023. PMID: 36161712 Free PMC article.
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.
Kumar S, Baizer L, Callander NS, Giralt SA, Hillengass J, Freidlin B, Hoering A, Richardson PG, Schwartz EI, Reiman A, Lentzsch S, McCarthy PL, Jagannath S, Yee AJ, Little RF, Raje NS. Kumar S, et al. Among authors: reiman a. Blood Cancer J. 2022 Jun 29;12(6):98. doi: 10.1038/s41408-022-00695-5. Blood Cancer J. 2022. PMID: 35768410 Free PMC article. Review.
36 results